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Abstract: Pancreatic β cells secrete insulin in order to maintain glucose homeostasis. 
However, various environmental stresses such as obesity have been shown to induce loss 
of secretory responsiveness in pancreatic β cells and pancreatic β cell apoptosis which can 
favor the development of type 2 diabetes (T2D). Indeed, elevated levels of free fatty acids 
(FFAs) have been shown to induce β cell apoptosis. Importantly, the chronic adverse 
effects of FFAs on β cell function and viability are potentiated in the presence of 
hyperglycaemia, a phenomenon that has been termed gluco-lipotoxicity. The molecular 
mechanisms underlying the pathogenesis of gluco-lipotoxicity in pancreatic β cells are not 
completely understood. Recent studies have shown that sphingolipid metabolism plays a 
key role in gluco-lipotoxicity induced apoptosis and loss of function of pancreatic β cells. 
The present review focuses on how the two main sphingolipid mediators, ceramides and 
sphingoid base-1-phosphates, regulate the deleterious effects of gluco-lipotoxicity on 
pancreatic β cells. The review highlights the role of a sphingolipid biostat on the  
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dysregulation of β cell fate and function induced by gluco-lipotoxicity, offering the 
possibility of new therapeutic targets to prevent the onset of T2D. 
Keywords: obesity; type 2 diabetes; gluco-lipotoxicity; islet of Langherans; ceramide; 
sphingosine-1-phosphate; sphingolipids; apoptosis; insulin; pancreas  
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1. Introduction 
In mammals, the levels of plasma glucose are tightly regulated to maintain normo-glycemia, and 
chronic hypoglycemia or hyperglycemia can result in injuries to various tissues. Insulin secreted by 
pancreatic β cells plays a major role in the maintenance of normo-glycemia. The biological machinery 
of pancreatic β cells enables them to regulate the rate of insulin secretion in response to variations in 
plasma glucose levels. Diabetes is a disease characterized by a chronic abnormal elevation of plasma 
glucose concentrations. Type 1 diabetes is an autoimmune disease against pancreatic β cells whereas 
type two diabetes (T2D) is a multi-factorial disease due to two principal dysfunctions: (1) a loss of 
insulin secretion and (2) insulin resistance, which is defined by the failure of insulin to elicit anabolic 
effects and stimulate glucose uptake in targeted tissues. 
The etiology of T2D is not well established but it is certain that loss of insulin secretion is directly 
linked to a loss of function and apoptosis of pancreatic β cells [1,2]. The insulin secretory capacity and 
reduction in β cell mass, observed during T2D, are thought to be amplified by the development of 
chronic hyperglycaemia, a phenomenon that has been termed “glucotoxicity” [2]. In addition to 
hyperglycaemia, accumulated evidence suggests that T2D is often associated with abnormalities in 
lipid metabolism and excessive levels of circulating lipids [3,4]. Indeed, it has been shown that 44% of 
diabetic patients are also obese [5], suggesting a link between obesity and T2D. Free fatty acids 
(FFAs) are important physiological fuels for islets, and act as supplemental nutrients able to potentiate 
insulin secretion in response to glucose [6,7]. However, chronically elevated levels of FFAs in 
circulation have been postulated to cause peripheral insulin resistance and impairment of β-cell insulin 
secretion, a phenomenon that has been termed “lipotoxicity” [8,9]. The molecular mechanisms 
underlying the pathogenesis of lipotoxicity in pancreatic β cells are not completely understood. 
Usually, low levels of FFAs are readily degraded by β-oxidation and are therefore non-toxic for  
β-cells. In contrast, chronic elevation of FFA levels raised the levels of long chain acyl-CoA  
(LC-CoA), which serve for complex lipid synthesis [8,10]. Interestingly, it has been proposed that a 
specific class of lipids, namely sphingolipids, and in particular ceramides, are important mediators of 
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FFA-induced β cell dysfunction and apoptosis [8]. In the present review, we will illustrate the 
mechanisms involved in pancreatic β cell lipotoxicity with a special focus on the role of ceramide 
metabolism at the molecular, cellular and systems levels. In addition, we will also discuss the role of 
other sphingolipid metabolites, such as sphingosine-1-phosphate (S1P) in the control of pancreatic β 
cell lipotoxicity. A better understanding of the role of sphingolipid metabolism involved in pancreatic 
β cell lipotoxicity may open up the potential for identification of pharmacological targets for the 
prevention and/or treatment of obesity associated T2D. 
2. Lipid Metabolism in Pancreatic β Cells 
Lipids have many biological functions; they serve as energy reserves, signalling molecules, and as 
major membrane components. In pancreatic β cells, lipids are extracted from plasma lipoproteins 
through lipoprotein lipases secreted by pancreatic β cells [11]. Lipids are converted into long chain 
acyl-CoA (LC-CoA) by the Acyl-CoA synthase in the cells [12]. LC-CoA may be then exported to 
mitochondria through carnitine palmitoyl-CoA transferase 1 (CPT-1) before being channeled into the 
β-oxidation pathway in order to provide energy. Interestingly, the fate of LC-CoA in pancreatic β cells 
is determined by intracellular glucose levels. At low glucose concentrations, FFAs are used to produce 
energy through the β-oxidation pathway [13]. In contrast, at high glucose concentrations, FFA 
metabolism will be preferentially oriented to lipid esterification. The main metabolites able to control 
the lipid metabolism in response to glucose appear to be malonyl-CoA and the LC-CoA [10]. High 
glucose concentrations accelerate its metabolism and increase intra-cytoplasmic citrate concentration 
through the Krebs cycle. The resulting citrate is then converted into malonyl-CoA by the acetyl-CoA 
carboxylase (ACC) [14–16]. Normally, malonyl-CoA is used as a substrate by FFA synthase (FAS) to 
produce FFAs; however in pancreatic β cells, the activity of FAS is lower than the activity of  
ACC [17], favouring the accumulation of malonyl-CoA. Interestingly, increased malonyl-CoA levels 
can inhibit CPT-1 activity leading to a reduction in mitochondrial transport of LC-CoA and its 
subsequent β-oxidation. The consequences of cytoplasmic FFA accumulation are the production of 
lipids derived by various metabolic pathways, such as esterification or diglyceride synthesis [14,18], or 
phospholipid synthesis [19,20]. In addition to these effects, the glucose also induces the expression of 
genes involved in lipogenesis via the transcriptional factor SREBP1c, which activates de novo 
lipogenic genes [21]. 
3. The Phenomenon of Pancreatic β Cell Gluco-Lipotoxicity 
It has been estimated by the World Health Organization that obesity is the main epidemic of the 
century, affecting about 1 billion people around the world [5]. Obesity has many deleterious 
physiological effects like cellular energy imbalances that can result in impairment of insulin secretion 
and the development of insulin resistance. Many hypotheses suggest a link between insulin resistance 
and obesity and T2D. Among these hypotheses, it has been proposed that hypoxia, fibrosis, and 
inflammation observed during obesity will impair adipose expansion and therefore the storage of 
excess FFAs. This phenomenon leads to ectopic storage of lipids [22–24]. The FFAs which 
accumulate in non-adipose tissues such as muscle and liver induce the activation of non-oxidative 
metabolic pathways. These pathways can lead to the production of toxic lipids. This phenomenon is 
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called lipotoxicity [22–24]. It has been shown that lipotoxicity can result in insulin resistance of 
skeletal muscle, hepatic steatosis [25,26] and impairment of insulin secretion by β-cells [8,9]. Indeed, 
palmitate, one of the most abundant FFAs in plasma, has detrimental effects on β-cell function, 
including impairment of glucose-induced insulin release [27,28], defective insulin gene  
expression [29–31], and induction of β-cell apoptosis [32–36]. Importantly, the chronic adverse effects 
of FFAs on β cell function and viability are potentiated by hyperglycaemia, a phenomenon that has 
been termed “gluco-lipotoxicity” [37,38]. It has been observed that β cell apoptosis induced by 
palmitate is highly potentiated in the presence of elevated glucose concentrations [32,39]. As proposed 
above, when glucose and lipid levels are simultaneously elevated, glucose inhibits FFA oxidation and 
stimulates the incorporation not only of endogenous LC-CoA but also excess FFAs into the synthesis 
of complex lipids [8,10,39]. Interestingly, among these lipids produced, ceramides have been 
suggested to be important mediators of FFA-induced β-cell dysfunction and apoptosis [8,39,40]. 
4. Sphingolipid Metabolism 
It is well established that sphingolipids are structural components of cellular membranes. However, 
several studies have now shown that sphingolipids have important roles in the regulation of some 
cellular processes [41,42]. Moreover, the deregulation of these processes plays a key role in the onset 
of pathologies affecting cellular proliferation and apoptosis [42–44]. Several pathways for sphingolipid 
metabolism have been described [45]. One of these pathways is the de novo synthesis pathway which 
is initiated on the cytoplasmic face of the endoplasmic reticulum (ER) (Figure 1). The first step of this 
pathway is the condensation of L-serine with palmitoyl-CoA to form 3-ketosphinganine. This reaction 
is catalyzed by serine palmitoyl-transferase (SPT) [41]. 3-Ketosphinganine is then reduced to 
dihydrosphingosine (DH-Sph) by 3-ketosphinganine reductase. The resulting DH-Sph acts as a 
substrate for ceramide synthases (CerS) leading to the production of dihydro-ceramides.  
Dihydro-ceramides can be transformed into ceramides by dihydroceramide desaturases [46]. 
Depending on the LC-CoA attached to the DH-Sph by CerS, the dihydroceramides and the ceramides 
are classified into different species with varying FA chain lengths (14–32 carbons in mammals) and 
saturation of the carbon chain [47]. Ceramides can be transported to the Golgi apparatus [48] where 
they are converted into sphingomyelin by sphingomyelin synthase or into glucosyl-ceramides by 
glucosyl-ceramide synthase. In addition to de novo synthesis, another metabolic pathway also leads  
to ceramide production and this involves the degradation of sphingomyelin into ceramide by 
sphingomyelinases. This process takes place in the lysosomal membrane and the cytoplasmic 
membrane [41]. In this web of sphingolipid metabolism, ceramides are considered as central players in 
the metabolism of sphingolipids. Indeed, ceramides are the precursors of many lipid messengers. For 
example, ceramides can be metabolized into sphingosine which is in turn phosphorylated to yield 
sphingosine-1-phosphate (S1P) [41]. Ceramides can also be phosphorylated by ceramide kinase to 
form ceramide-1-phosphate [41]. 
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Figure 1. Synthesis of sphingolipids in mammalian cells. Two main pathways to produce 
sphingolipids exist in mammals. The de novo pathway of synthesis starts on the 
cytoplasmic face of the endoplasmic reticulum (ER). The first step of this pathway is the 
condensation of L-serine with palmitoyl-CoA to form a 3-ketosphinganine. This reaction is 
catalyzed by serine palmitoyl-transferase (SPT). 3-Ketosphinganine is then reduced to 
form dihydrosphingosine (DH-Sph) by 3-ketopshinganine reductase. DH-Sph is a substrate 
of ceramide synthases (CerS) which produce dihydro-ceramide. Dihydroceramides are 
transformed into ceramides by dihydroceramide desaturase. Ceramide can be transported to 
the Golgi apparatus to be transformed into more complex sphingolipids such as 
sphingomyelin and glucosyl-ceramides. A second synthesis pathway is the catabolic 
pathway that leads to the degradation of sphingomyelin (SM) into ceramides by 
sphingomyelinases. This process takes place in the lysosomal and plasma membranes. 
 
5. Ceramide and Pancreatic β Cell Gluco-Lipotoxicity 
As noted above, among the lipids produced during lipotoxicity, ceramides have been implicated in 
the deleterious effects of gluco-lipotoxicity on pancreatic β cells and in a more general manner, on 
T2D and obesity. For example, patients with T2D present an increase in sphingolipid levels in plasma, 
muscle, adipose tissue and liver [25,49]. The accumulation of sphingolipids has been correlated with 
an increase in insulin resistance [50,51], loss of function and death of pancreatic β cells [8]. 
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Additionally, sphingolipids also appear to also play a role in the complication of obesity and T2D. 
Interestingly, the two forms of SPT (SPT 1 and 2) have a Km for L-serine and the palmitoyl-CoA near 
to their physiological concentrations [52,53], and as such, are sensitive to relatively small variations in 
the concentrations of their substrates. Moreover, condensation of L-serine and palmitoyl-coA is the 
rate-limiting step in de novo synthesis of ceramides [54]. These two characteristics of SPTs suggest 
that excessive concentrations of palmitate and its activated form palmitoyl-CoA in a cell can induce 
the aberrant production of ceramides. It has been shown that diminution of pancreatic β cell mass and 
loss of insulin secretion are correlated to an increase in intracellular ceramide levels and SPT 
expression in islet of Langerhans of obese Zucker diabetic fatty (ZDF) rats [35].  
5.1. Effect of Ceramide on Pancreatic β Cell Function 
Previous studies have demonstrated that cellular permeable analogues of ceramide impaired insulin 
production in pancreatic β-cells [55]. Under gluco-lipotoxic conditions, several studies showed a 
correlation between de novo ceramide synthesis and defective insulin expression in islet of  
Langerhans [8]. In islet of Langerhans and pancreatic β cell lines, ceramide dependent inhibition of 
insulin expression is mediated by the dephosphorylation of protein kinases, ERK1/2 by PP2A [56,57]. 
Moreover, the de novo ceramide pathway inhibits the nuclear translocation of two important 
transcription factors, PDX-1 and Mafa, for insulin-induced gene expression [8]. However, the 
intracellular signaling pathways mediating these effects are mostly unknown. Previous studies have 
shown that glucose regulates insulin-induced gene transcription via the serine/threonine Per-Arnt-Sim 
domain-containing kinase (PASK) [56]. Interestingly, palmitate decrease glucose-induced expression 
of PASK mRNA and protein levels [56], suggesting that ceramides may function as negative 
regulators of PASK. It appears that in pancreatic β cells, inhibition of ceramidase, which increased 
intracellular levels of ceramides, also leads to a reduction in insulin expression [57]. More recently, 
genetic deletion of sphingomyelin synthase 1 (SMS1) has been shown to induce accumulation of 
ceramides in islet of Langerhans, dysfunction of mitochondria and the subsequent inhibition of insulin 
secretion [58]. In Yano’s study, accumulation of ceramides affected mitochondria membrane integrity 
and induced an excessive production of ROS which were partially responsible for the defect in insulin 
secretion in pancreatic β cells [58]. Pharmacological inhibition of SMS or down-regulation by siRNA 
of the ceramide transporter (CERT), which regulate ceramide transport between the ER and Golgi 
apparatus, increased dysfunction of pancreatic β cells induced by palmitate by affecting binding of 
transcription factors to the insulin promoter [59]. Altogether, these results suggest that ceramide 
accumulation, either through the induction of de novo synthesis or reduced conversion into more 
complex sphingolipids, is involved in loss of function in pancreatic β cells. 
5.2. Effect of Ceramide on Pancreatic β Cell Survival 
It has been shown that ceramide analogues can block proliferation and induce apoptosis of β cells 
and islets of Langerhans in culture [60,61]. De novo ceramide synthesis induced by palmitate has also 
been implicated in pancreatic β cell apoptosis [8,39]. Indeed, inhibition of de novo ceramide synthesis 
abrogates pancreatic β cell apoptosis induced by palmitate [36,39,62]. More importantly, treatment  
of ZDF rats with a potent inhibitor of SPT, cyclo-serine, attenuated islet of Langerhans apoptosis  
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and prevented the appearance of hyperglycemia [35]. Ceramide accumulation induced by  
(gluco)-lipotoxicity induces pancreatic β cell apoptosis through different pathways. FFAs have been 
shown to induce accumulation of ceramides in ER of pancreatic β cells [40,63]. To date, the mechanisms 
used by (gluco)-lipotoxicity to block the transport of ceramides remain unknown. However, ceramide 
accumulation leads to ER stress which plays a key role in lipotoxic induced apoptosis [40,63,64]. 
Biden and co-workers showed that localized ceramide production and the associated decrease of SM 
levels in the ER in response to lipotoxicity is important to initiate ER stress in β cell [40,63]. Ceramide 
induced pancreatic β cell apoptosis is mediated by mitochondrial dysfunction and ROS  
production [60,61]. This result is also supported by the observation that ceramide dependent ROS 
production induced by gluco-lipotoxicity inhibits insulin secretion [8]. Evidence to date suggests that 
ceramide induce apoptosis through mitochondria injuries and subsequent production of ROS [65]. 
Nevertheless, the role of ROS in gluco-lipotoxicity is still unclear because in some cases, ROS have 
been excluded from ceramide-induced loss of function or apoptosis of pancreatic β cells [40,66]. 
Moreover, other hypotheses have been proposed about cellular signals involved in apoptosis of 
pancreatic β cell induced by ceramides. For example, it has been proposed that β cell apoptosis is 
induced through the activation of PP2A and the subsequent dephosphorylation of AKT [67], as seen in 
muscle tissues [68]. 
5.3. Role of Different Ceramide Species in Gluco-Lipotoxicity Induced Pancreatic β Cell Apoptosis  
Ceramide species are distinguishable by the length and/or saturation of their N-acyl chains [47,69,70]. 
Because ceramide species have many biological roles depending on the cell type and on the inducing 
signals for their production [47], it is therefore important to determine changes in ceramide species in 
response to biological stimuli. Indeed, recent studies have reported distinct cellular functions for 
ceramides with specific N-acyl chain lengths [47,70]. The emergence of lipidomic analysis in the field 
of sphingolipid metabolism allows us to determine the effect of various treatments, not only on 
ceramide accumulation but also on changes in levels of ceramide species within the ceramide  
pool [52]. In pancreatic β cells, it appears that gluco-lipotoxicity modifies the levels of specific 
ceramide species, specifically C18:0, C22:0 and C24:1 [39]. In mammals, the variety of ceramide 
species relies on the existence of a family of enzymes, the ceramide synthases (CerS) [47,70]. Six CerS 
have been identified and they possessed a characteristic substrate preference for particular fatty  
acyl-CoA [47,70]. Interestingly, this increase in ceramide species is associated with an augmentation 
of CerS4 expression, which was found to play a critical role in pancreatic β cell apoptosis [39]. 
Collectively, the results suggest that gluco-lipotoxicity induces β cell apoptosis not only through the 
induction of de novo ceramide biosynthesis, but also through the formation of ceramides with specific 
carbon chain lengths rather than an overall increase in ceramide content. This hypothesis is supported 
by a recent study showing that pancreatic β cell apoptosis is potentiated when high glucose levels 
increased expression of FA elongase 6 (Elovl6) [71], an enzyme which catalyzes FFA elongation [72]. 
Importantly, the activity of Elovl-6 is mostly involved in elongation of de novo-synthesized palmitate 
to produce stearate, suggesting that gluco-lipotoxicity could mediate β-cell apoptosis at least through 
ceramide C18:0 by a concomitant up-regulation of CerS4 and Elovl-6. Recently, Prentki and  
co-workers have shown that gluco-lipotoxicity induced early changes in lipid partitioning in order to 
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induce β-cell dysfunction and apoptosis [73]. Indeed, gluco-lipotoxicity induced the expression of 
proteins which favored FFA esterification, such as SCD-1 through FFA desaturation, and decreased 
the expression of enzymes involved in lipid oxidation, such as the β subunit of AMP-kinase. These 
results suggest that in addition to downstream lipid partitioning induced by gluco-lipotoxicity, the 
synthesis of specific ceramide species could also play a critical role in β cell apoptosis. However, the 
precise role of specific ceramide species in β cell dysfunction induced by gluco-lipotoxicity remains to 
be clarified. Indeed, a recent study showed that the inability of CerS2 knock-out mice to synthesize 
C22–C24 ceramide species did not result in defective insulin secretion [74]. Therefore, it will be 
important, in the future, to validate these observations in vivo by using rodent models of T2D 
associated to obesity, and ultimately in human islets of Langerhans in order to identify potent 
therapeutic targets to limit pancreatic β cell gluco-lipotoxicity. 
6. Role of Sphingoid Base Phosphates in T2D 
During the past decade, other sphingolipid metabolites, namely sphingoid base phosphates, have 
been shown to have a role in T2D. The sphingoid base phosphates are S1P and its analogue 
dihydroS1P, which are respectively produced by phosphorylation of Sph and DH-Sph by sphingosine 
kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) [45]. S1P is known to induce proliferation, 
survival, migration and calcium mobilization in many cell types [42]. In T2D patients and rodent 
models of T2D, the activity of SphK1 and/or mRNA of SphK1 are increased in myocardium [75]. 
Interestingly, palmitate [76] or glucose [77,78], taken separately, not only increased sphingoid base 
phosphate levels but also SphK1 activity in different cell types such as muscle and endothelial cells. 
Moreover, treatment with S1P analogs protected cells from apoptosis [79,80] induced by 
hyperglycemia. In addition, in vivo over-expression of SphK1 gene in KK/Ay type 2 diabetic mice [81] 
or treatment mice under high fat diet with S1P analog [82] reduced the deleterious appearance of 
insulin resistance and T2D. Nevertheless, the role of the SphK1/S1P axis in T2D is still unclear. 
Indeed, induction of diabetes by an injection of streptozotocin leads to the activation of SphK1 
associated to an inflammatory phenotype in vascular endothelium and retina [77,83]. Moreover, the 
SphK1/S1P axis appears to stimulate the expression of cytokine by adipocytes isolated from ob/ob 
mice [84] and in obese T2D patients [85]. 
6.1. Sphingoid Base Phosphates and Insulin Secretion 
In pancreatic β cells, SphK1 and SphK2 and four of the five S1PR are expressed [85–87]. 
Expression and activity of SphK1 and SphK2 are stimulated by cytokines such as IL1β, TNFα and 
interferon-γ, but also by glucose and acetylcholine [77,87]. The role of S1P in insulin secretion is still 
unclear. Indeed, it has been shown that adding S1P to culture medium of pancreatic INS-1 β cell line 
and islets of Langerhans inhibits insulin secretion in response to glucose potentiated by GLP-1. The 
S1P1 receptor, coupled to Gi appears to be involved in this phenomenon [86]. In contrast to this study, 
S1P was found to stimulate secretion of insulin in islet of Langerhans [88] and in pancreatic HIT-T 15 
β cell line [89,90]. Interestingly, Ozcan and colleagues showed that SphK2 plays a critical role in S1P 
production and insulin secretion induced by glucose [90]. To date, SphK1 has not been implicated in 
the control of insulin secretion. However, most of these studies have been conducted in pancreatic β cell 
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lines or isolated normal islets. It will thus be important to investigate the in vivo role of sphingoid base 
phosphates by analyzing insulin secretion in available knock-out mice for SphK1 and SphK2 [91,92]. 
6.2. Sphingoid Base Phosphates Pancreatic β Cell Survival 
In pancreatic β cells, the SphK1/S1P axis plays a critical role in survival. Indeed, adding S1P to 
culture medium of human or murine islets of Langerhans inhibited apoptosis induced by  
cytokines [93]. In this case, the anti-apoptotic effect of S1P is mediated by the S1P2 or S1P3 receptors, 
and the activation of the PKC pathway [93,94]. Interestingly, activation of SphK by glucose has also 
been implicated in β cell proliferation [76]. It was observed that gluco-lipotoxicity increased sphingoid 
base phosphates via up-regulation of the SphK1 pathway in pancreatic β cells [88]. Pharmacological 
inhibition of SphK activity drastically potentiates β cell apoptosis whereas over-expression of SphK1 
partially inhibits β cell apoptosis induced by gluco-lipotoxicity. The anti-apoptotic effect of sphingoid 
base-1-phosphates are likely to be mediated by opposing signaling pathways to ceramide-induced 
apoptosis. Indeed, over-expression of SphK1 not only inhibited lipotoxicity-induced loss of mitochondrial 
transmembrane potential and cytochrome c release in pancreatic β cells [95] but also impaired protein 
trafficking between ER and Golgi which contributed to lipotoxicity-induced ER stress [88]. Another 
anti-apoptotic effect of sphingoid base phosphates involved the alteration of lipotoxicity-induced 
ceramide synthesis in pancreatic β cells [88]. While the mechanisms for this latter process remain to be 
established, it could potentially involve inhibition of CerS by S1P [96]. The in vivo protective role of 
SphK1 against pancreatic β cell apoptosis induced by gluco-lipotoxicity was supported by a recent 
study by Qi and co-workers who showed that while a high fat diet-fed wild-type (WT) mice developed 
glucose intolerance, all high fat diet-fed Sphk1 knock-out mice manifested evident diabetes, a 
phenomenon due to a drastic decrease in pancreatic β cell mass [95]. Nevertheless, the in vivo role of 
SphK1 still remains unclear since a recent study showed that under high fat diet-fed mice, SphK1 
deficiency was associated with enhanced insulin signaling in adipose and muscle tissues and improved 
systemic insulin sensitivity and glucose tolerance [85]. Despite this recent study, the anti-apoptotic role 
of sphingoid base phosphates in pancreatic β cells are in agreement with the work of Boslem et al., who 
showed that ceramide removal from the ER, by favoring their conversion into glucosylceramides [40],  
is critical for β cell survival under gluco-lipotoxic conditions. Our findings suggest that the 
SphK1/sphingoid base phosphates axis could constitute a new therapeutic strategy for preventing 
pancreatic β cell death and thus the onset of T2D associated with obesity. In the future, it will be 
important to identify potent activators of the SphK1/sphingoid base phosphates axis in pancreatic β 
cells. In support of this, a recent work by Holland et al. [97] showed that adiponectin can preserve 
pancreatic β cell function by shifting the ceramide/S1P ratio towards higher relative levels of S1P. 
7. Conclusions 
Because of their inter-convertibility and opposing effects, the dynamic balance between sphingoid 
base phosphates and ceramides has been proposed to be an important factor that determines cell  
fate [42], a concept called the sphingolipid biostat. The results of recent in vitro and in some cases  
in vivo studies lend credence to the observation that pancreatic β cell apoptosis induced by  
gluco-lipotoxicity is regulated by such a sphingolipid biostat (Figure 2). The existence of this biostat 
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offers the possibility to find new therapeutic targets in order to limit pancreatic β cells failure observed 
during obesity, and therefore to prevent the appearance of T2D. 
Figure 2. Role of sphingolipid biostat in β-cell apoptosis during gluco-lipotoxicity. 
Palmitate has been shown to induce ceramide accumulation by a dual mechanism involving 
serine palmitoyl-transferase (SPT) and the formation of ceramides with specific N-acyl 
chain lengths by ceramide synthase 4 (CerS4). Fatty acid elongase 6 (Elovl-6) provides 
preferential substrate for CerS4 by converting palmitate into stearate. Ceramides reduces 
insulin expression through inhibiting the binding of pancreatic and duodenal homeobox 1 
(PDX-1) and Mafa transcriptional factors to insulin promoter. Ceramide accumulation can 
also induce pancreatic β cell apoptosis. However, palmitate also induces sphingosine 
kinase 1 (SphK1) expression, which will channel the preferential metabolic flow of newly 
formed dihydrosphingosine (DHSph) towards its phosphorylation into dihydrosphingosine-
1-phosphate (DHS1P) and increase S1P levels. Accumulation of these sphingoid base 
phosphates in the ER will play a protective role against palmitate-induced  
ceramide-dependent apoptotic β cell death. Sphingoid base phosphates inhibit ceramide 
synthesis by acting probably on CerS4 activity and restore protein trafficking in the 
endoplasmic reticulum (ER), alleviating ER stress and attenuating cytochrome C (CytC) 
release from mitochondria. DH-Cer: dihydro-ceramides; Sph: sphingosine. 
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